Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. - Wikidata - wikimedia - TriplyDB

Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.

Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.

http://www.wikidata.org/entity/Q42180401

about

Systemic manifestations of hepatitis C infection Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Extrahepatic manifestations of hepatitis C infection: navigating CHASM.Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.HCV Treatments and Their Integration Into Rheumatology.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.Extrahepatic manifestations of HCV: the role of direct acting antivirals.Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents.Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection.Editorial: Benefit of Direct-Acting Antiviral Therapy For Cryoglobulinemia due to Hepatitis C Infection.From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study.Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy.Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication.Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?Persistent Hepatitis C Virus−Associated Cryoglobulinemic Glomerulonephritis in Patients Successfully Treated With Direct-Acting Antiviral Therapy.Hepatitis C mixed cryoglobulinemia with undetectable viral load: A case series Correlation of CCR5 and NLRP3 gene polymorphisms with renal damage due to hepatitis C virus-related cryoglobulinemia

P2860

Q26746040-9573DA12-6092-4916-9715-C65739153B52 Q26750997-E61C5A94-05D7-402D-BFA2-8B9296521907 Q26752433-32190746-655D-408B-ACD1-A01704EB9F7E Q26781743-45F71B7B-5A0A-4D1D-9342-909E52C5F41F Q28072257-D164E9B3-CC09-4640-B635-FE3CB1D8B2E1 Q30251847-E3F14F5D-F052-4791-98E1-CE386AC71880 Q36010828-6547FF72-0696-44FF-B233-51EACF084B68 Q36165309-5F38F77B-7060-4376-9B84-52F908423DC3 Q36194392-993016FE-A47E-48C0-9EA0-1B4F5EAE4C41 Q36479541-25A2E087-A595-4BB1-9E15-F13703A271F8 Q38393228-97E98620-1BF3-4CDD-9447-F16FB07CCADB Q38538199-82432946-70C6-4EA6-9B47-374923A566A0 Q38602682-6A57E3D8-781D-47B0-B101-E201300ED579 Q38676280-5EF8E287-53A1-4D22-B193-5E2935950D1E Q38684508-2E2DFF9E-4B46-403D-AEDA-B2E0525E05CE Q38712605-680DF0F0-909C-4E4A-B90D-3CB7B0CFA581 Q38806948-46677611-B9AA-4AD7-80A9-C8E59DEC97E0 Q38909316-C94C57C2-11D5-4E11-BA2B-3EBDB236802A Q38933599-076AF1A1-4920-4F24-A1B3-0DB9DC5B139B Q40088333-26B406A7-2F57-4A2D-98D1-7062BC880F6B Q40098395-7E93DF2A-A7B7-4336-9E95-FF87F4BD0FD2 Q40135838-D1CDE29A-CA06-4C7C-80F4-80B416D05EB4 Q40216845-9A1BF9F1-0F07-4EC5-8139-34370BD390F6 Q40341541-8317A10E-5CEB-40A7-9B37-BDD010FB84C3 Q40362365-F60759FE-D227-423B-8FE3-E14A318D0E79 Q40404776-0718C697-289C-49CD-AD69-1CF82C8699BE Q40528517-8ED27FCE-B36B-4A08-BF86-2AD4160F2A6F Q45335091-F1FE5CB3-3719-41E4-8E48-B2CF7D194165 Q47171530-9C7F343F-BB10-44C1-94CD-C66B7EE504DA Q47549008-460DA7B9-B633-4A07-A5AE-5E7D62B77627 Q47556234-57294D2D-A246-4188-B59F-A99361A38878 Q50131589-4FD7A91F-10F0-4D34-951B-9D70E6F5BEF8 Q54216578-51F5C3BD-F783-41C7-B294-1E14B73453BB Q55456275-986152D0-AF01-4263-AADA-1BD5912B4F23 Q58777865-C0ED3898-D38D-4254-918C-EDE7167A89D5 Q58804680-AC3DA343-5317-47B2-9B7D-874A40CF8C90

P2860

Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.

http://www.wikidata.org/entity/Q42180401

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@en

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@nl

type

label

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@en

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@nl

prefLabel

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@en

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@nl

P1433

Q42180401-CF0E0DB7-7A10-4A8C-A617-916E9A2DB898

P1476

Q42180401-9EB14728-6F24-4603-BFA2-6AE928BAE516

P2093

Q42180401-29F6169F-DE31-47E4-9675-9745FAD8B6ED

Q42180401-2F741425-8EE0-4009-8E73-288B32276D4D

Q42180401-42C70832-1BCF-463D-8EE1-279144656E19

Q42180401-48D90F31-D279-4CDE-A73A-64F34DCBE3CA

Q42180401-4FEA165E-D253-4D33-9F78-E757AD265A1B

Q42180401-504B4EFB-26DD-456F-B63A-001EE3442B12

Q42180401-52CB58ED-40C5-49DB-AB0D-BC10825A18DD

Q42180401-82851DAC-8732-4474-89C6-F25DD63FA320

Q42180401-C88440FE-6CC2-4EAF-A77C-DEAA51B30521

Q42180401-ED20B385-91A6-46D9-929A-CA260B09BC74

P2860

Q42180401-08978F9A-D032-463F-AE43-5E9297FE14FE

Q42180401-0BCA1F5F-8969-4897-B205-1CAD824611EB

Q42180401-11B97F17-F936-46C4-8EF0-5BB5A8A6123E

Q42180401-1C4D45A8-010A-4CCD-AE8D-C6FAC5ACE99D

Q42180401-275660F3-5E70-4216-A4EB-E8A0AC360240

Q42180401-28F623BE-7288-4369-A793-11CE4E1B7001

Q42180401-2A4B5BBE-AF67-4CA8-A670-53F968C51BD0

Q42180401-2BF975B0-F59A-4EA4-AB86-980D0AD61EF3

Q42180401-2C1DEB55-8FDF-4E18-AE0A-3EC6DA932BA2

Q42180401-30CA91EE-9E9E-45A1-B77F-75139852E1A7

P304

Q42180401-1EAB283A-E958-4CC7-AF28-F2FBA7D44CD3

P31

Q42180401-59CFAE54-344E-4AFF-B6E0-16AB72A2A487

P356

Q42180401-B8582DF4-1546-4C11-9A1C-8B66AC1F8804

P407

Q42180401-F2B6F10A-C7E8-4E5F-8751-95EE5C1990B3

P433

Q42180401-9CD05562-A6D0-4483-B1D0-72268A4CFCBC

P478

Q42180401-05F28479-FBE9-4C26-9642-C5465841AB08

P50

Q42180401-84863DDA-061E-4135-8E83-BB19CA019600

Q42180401-8D6990EE-7107-43B6-9873-95ADDD6CCE56

Q42180401-C436D697-F0E8-408D-85AC-32F90C6EE8CF

Q42180401-CD084FAA-DC24-4BB3-A7F2-2B3BD07DC566

P577

Q42180401-28DAC208-3CCD-4262-B9D6-9984C68C3BBD

P5875

Q42180401-E2592F00-9E79-40E3-AFB2-656E896F2522

P698

Q42180401-B54B1C8E-83A8-411A-96C4-1EDBAEAD057D

P356

P1433

P1476

Long-term effect of HCV eradic ...... led, open-label, cohort study.

@en

P2093

Alessia Piluso

http://www.w3.org/2001/XMLSchema#string

Alessio Fabbrizzi

http://www.w3.org/2001/XMLSchema#string

Barbara Boldrini

http://www.w3.org/2001/XMLSchema#string

Claudio Iannacone

http://www.w3.org/2001/XMLSchema#string

Elisa Fognani

http://www.w3.org/2001/XMLSchema#string

Jessica Ranieri

http://www.w3.org/2001/XMLSchema#string

MaSVE Study Group

http://www.w3.org/2001/XMLSchema#string

Monica Monti

http://www.w3.org/2001/XMLSchema#string

Teresa Urraro

http://www.w3.org/2001/XMLSchema#string

Umberto Arena

http://www.w3.org/2001/XMLSchema#string

P2860

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C

Diagnosis, management, and treatment of hepatitis C: an update

Diagnosis, management, and treatment of hepatitis C

Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes.

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24

Preliminary classification criteria for the cryoglobulinaemic vasculitis.

Hepatitis C virus (HCV) infection: a systemic disease.

Extrahepatic manifestations of hepatitis C virus infection.

Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.

P304

1145-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27623

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Anna Linda Zignego

P577

2015-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268873196

http://www.w3.org/2001/XMLSchema#string

P698

25431357

http://www.w3.org/2001/XMLSchema#string